Sarcoidosis is an immune-mediated disease characterized by collections of immune cells called granulomas.  The lungs and lymph nodes are most commonly involved, but many different organs in the body can be affected. 

If you have been diagnosed with sarcoidosis, you may be eligible for a study with a new investigational treatment called sarilumab (Kevzara).  This drug blocks a molecule that stimulates the immune system and causes inflammation.

QUALIFIED PARTICIPANTS INCLUDE:

• Adults who are at least 18 years old

• Those diagnosed with sarcoidosis based on a positive biopsy

• Those with ongoing disease despite treatment with steroids medications such as prednisone

• Additional criteria apply

THOSE THAT QUALIFY MAY:

• Receive study related care from a Stanford rheumatologist at no cost

• Receive compensation for time and travel

• Have access to a medication being investigated for the treatment of sarcoidosis

LEARN MORE TODAY!

Please contact Dr. Matthew Baker at mbake13@stanford.edu